Understanding how lung cancer interacts with its environment during treatment
Official title: The Delta Ecology of NSCLC Treatment
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11064240 · Data updated 2026-11-12
This study is looking at how non-small cell lung cancer interacts with the surrounding lung environment to understand how tumors grow and change, with the hope of finding better treatment options that are more suited to each patient's unique cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | September 15, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $67,476 |
| NIH project number | 3U54CA274507-02S1 |
| Project ID | NIH-11064240 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with non-small cell lung cancer, particularly those with specific driver mutations such as RAS, EGFR, or ALK.
✕Less likely to help
Patients with other types of lung cancer or those who do not have the specific mutations targeted by this research may not benefit from the findings.
What this research studies
This research investigates the dynamic relationship between non-small cell lung cancer (NSCLC) and the lung microenvironment, focusing on how tumors evolve and respond to treatment. By analyzing changes in both cancer cells and surrounding host cells, the study aims to uncover the ecological factors that influence tumor progression and resistance to therapies. The approach involves using clinical data and various experimental models to quantify and optimize treatment strategies based on these ecological dynamics. Patients may benefit from insights that could lead to more effective treatment options tailored to their specific cancer characteristics.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with non-small cell lung cancer, potentially enhancing survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in understanding cancer ecology and its impact on treatment outcomes, suggesting that this approach could yield valuable insights.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Anderson, Alexander Robertson Allan — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Anderson, Alexander Robertson Allan
Related research
Other NIH-funded projects on the same topics.
-
7-marker protein test to predict NSCLC response to anti-PD-1 therapy
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
-
Barcoded tumor sequencing to map radiation-triggered immune effects in lung cancer
This project uses barcoded tumor models and sequencing to uncover how adding radiation to immunotherapy might spark whole-body immune attacks against non-small cell lung cancer.
-
Targeting the cancer-friendly secretory system in a common lung cancer cancer subtype
A study tests new ways to block the secretory system inside tumor cells to stop growth and spread in a major subtype of non-small cell lung cancer.
-
Predicting outcomes and side effects in stage III NSCLC with AI-driven imaging
A multimodal AI approach uses chest CT and tissue images to forecast how patients with unresectable stage III NSCLC will respond to durvalumab after chemoradiotherapy and who might develop pneumonitis.
-
ATM kinase as a target to help NSCLC with brain metastases respond to treatment
A study from Yale University tests whether blocking ATM kinase can delay or overcome treatment resistance in people with advanced non-small cell lung cancer that has spread to the brain and other organs.
-
Understanding how cancer-supportive tissue affects resistance to ALK and KRAS therapies
A research team will study how the tumor’s surrounding tissue changes as cancer cells become resistant to ALK and KRAS-targeted treatments, aiming to find better combination strategies for long-lasting remission.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.